Stratos Wealth Partners LTD. Purchases Shares of 6,327 Exelixis, Inc. (NASDAQ:EXEL)

Stratos Wealth Partners LTD. acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 6,327 shares of the biotechnology company's stock, valued at approximately $234,000.

Other institutional investors also recently modified their holdings of the company. EULAV Asset Management raised its position in shares of Exelixis by 10.4% during the first quarter. EULAV Asset Management now owns 530,000 shares of the biotechnology company's stock worth $19,568,000 after acquiring an additional 50,000 shares during the last quarter. TD Private Client Wealth LLC increased its position in Exelixis by 29.5% in the first quarter. TD Private Client Wealth LLC now owns 12,944 shares of the biotechnology company's stock worth $478,000 after purchasing an additional 2,950 shares during the period. Envestnet Asset Management Inc. raised its holdings in Exelixis by 23.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company's stock worth $9,159,000 after purchasing an additional 47,845 shares during the last quarter. Penserra Capital Management LLC acquired a new position in Exelixis during the 1st quarter valued at about $1,298,000. Finally, Concurrent Investment Advisors LLC bought a new position in shares of Exelixis in the 1st quarter valued at about $457,000. 85.27% of the stock is owned by institutional investors.

Insider Activity at Exelixis

In related news, EVP Patrick J. Haley sold 126,383 shares of the company's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $47.96, for a total transaction of $6,061,328.68. Following the sale, the executive vice president owned 446,459 shares in the company, valued at approximately $21,412,173.64. This represents a 22.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Stelios Papadopoulos sold 36,508 shares of the stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $44.35, for a total value of $1,619,129.80. Following the transaction, the director directly owned 1,279,416 shares of the company's stock, valued at $56,742,099.60. This trade represents a 2.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 458,113 shares of company stock worth $21,024,817. 2.82% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on EXEL. Stifel Nicolaus boosted their price target on shares of Exelixis from $36.00 to $38.00 and gave the stock a "hold" rating in a research note on Wednesday, May 14th. HC Wainwright increased their price target on Exelixis from $47.00 to $53.00 and gave the company a "buy" rating in a research note on Monday, June 30th. UBS Group set a $43.00 price objective on Exelixis and gave the stock a "neutral" rating in a research note on Friday, July 11th. Morgan Stanley reiterated an "overweight" rating and issued a $47.00 price objective (up previously from $40.00) on shares of Exelixis in a report on Wednesday, May 14th. Finally, Guggenheim set a $45.00 target price on Exelixis and gave the stock a "buy" rating in a report on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $45.28.

Exelixis Stock Down 0.9%

EXEL traded down $0.40 during trading on Friday, hitting $44.47. The company had a trading volume of 1,771,854 shares, compared to its average volume of 2,527,809. The company has a market capitalization of $12.13 billion, a PE ratio of 20.21, a PEG ratio of 0.90 and a beta of 0.28. Exelixis, Inc. has a one year low of $22.20 and a one year high of $49.62. The firm's 50-day moving average price is $43.01 and its 200 day moving average price is $38.33.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.